Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma. 
        		 
                    		   Ding X, Huang T, Peng C, Ahn KS, Andersen JB, Lewinska M, Cao Y, Xu G, Chen G, Kong B, Friess H, Shen S, Roberts LR, Wang L, Zou X. 
        		              
                         J Cancer 
                         11 :
                    		 2020 
                    		 2241-2251 
                        
                       
                    		   1 
        	              
                   
                     
                       
                         Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. 
        		 
                    		   Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. 
        		              
                         J Hepatol 
                         73 :
                    		 2020 
                    		 315-327 
                        
                       
                    		   123 
        	              
                   
                     
                       
                         Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities. 
        		 
                    		   Dinh TA, Sritharan R, Smith FD, Francisco AB, Ma RK, Bunaciu RP, Kanke M, Danko CG, Massa AP, Scott JD, Sethupathy P. 
        		              
                         Cell Rep 
                         31 :
                    		 2020 
                    		 107509 
                        
                       
                    		   19 
        	              
                   
                     
                       
                         New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. 
        		 
                    		   Colyn L, Alvarez-Sola G, Latasa MU, Uriarte I, Herranz JM, Arechederra M, Vlachogiannis G, Rae C, Pineda-Lucena A, Casadei-Gardini A, Pedica F, Aldrighetti L, López-López A, López-Gonzálvez A, Barbas C, Ciordia S, Van Liempd SM, Falcón-Pérez JM, Urman J, Sangro B, Vicent S, Iraburu MJ, Prosper F, Nelson LJ, Banales JM, Martinez-Chantar ML, Marin JJG, Braconi C, Trautwein C, Corrales FJ, Cubero FJ, Berasain C, Fernandez-Barrena MG, Avila MA. 
        		              
                         J Exp Clin Cancer Res 
                         41 :
                    		 2022 
                    		 183 
                        
                       
                    		   6 
        	              
                   
                     
                       
                         Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma.  
        		 
                    		   Silvestri M, Nghia Vu T, Nichetti F, Niger M, Di Cosimo S, De Braud F, Pruneri G, Pawitan Y, Calza S, Cappelletti V. 
        		              
                         Cancer Med 
                         12 :
                    		 2023 
                    		 10156-10168 
                        
                       
                    		   5 
        	              
                   
                     
                       
                         Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer. 
        		 
                    		   Jansson H, Cornillet M, Sun D, Filipovic I, Sturesson C, O'Rourke CJ, Andersen JB, Björkström NK, Sparrelid E. 
        		              
                         Front Oncol 
                         13 :
                    		 2023 
                    		 1169537 
                        
                       
                    		   1 
        	              
                   
                     
                       
                         Molecular profiling reveals potential targets in cholangiocarcinoma. 
        		 
                    		   Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK. 
        		              
                         World J Gastroenterol 
                         29 :
                    		 2023 
                    		 4053-4071 
                        
                       
                    		   0 
        	              
                   
                     
                       
                         Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches. 
        		 
                    		   Porreca V, Barbagallo C, Corbella E, Peres M, Stella M, Mignogna G, Maras B, Ragusa M, Mancone C. 
        		              
                         Cancers (Basel) 
                         16 :
                    		 2024 
                    		 2889 
                        
                       
                    		   0